BioAmber Inc fka BIOAQ

[iron-eagle]

That’s funny but wildly inaccurate. Let’s start with who’s not paying: LCY Biosciences that bought the assets as part of the Offer. The APA clearly states they are not responsible for any broker or finder fees. Now let’s focus on where the money is coming from: Taiwan. Bioamber having a figi on the Taipei exchange confirms that. Now who: ultimately LCY Chemical or LCY Group as parent and even perhaps through a subsidiary. How do I know that? Because mica told the losing bidder the winning bid was a share purchase. Given that Visolis was brought in solely to help them because they don’t know sheet about fermentation that clearly narrows it down to LCY; again the figi on the Taipei exchange confirms that and the Visolis transaction being funded by LCYT who is listed on the Taipei exchange collaborates that as well. The rest of the details were clearly omitted and pwc made sure they had an extraordinary release for omissions made during the proceedings just for that. However they state clearly that there were “forecast fees for the sale of the Company” well after the asset portion of the “Offer” was complete so I guess technically they didn’t omit it in very vague and general terms lol. And don’t forget there are “subscription price” options to buy into a company; most likely LCY when they go public via kkr SPAC.

Did that clear it up? Neverember 32 coming and it’s going to be a real bummer for some.

Cordially,
IE